Erythromycin cyclocarbonate

Research use only, not for human use.

A derivative of Erythromycin that inhibits protein synthesis of bacteria by binding to the 50S ribosome.

A derivative of Erythromycin that inhibits protein synthesis of bacteria by binding to the 50S ribosome, shows activity against Gram-positive and some Gram-negative microorganisms.

Erythromycin is used in treatment of respiratory, gastrointestinal, and genital tract infections, as well as skin and soft tissue infections. Erythromycin, with its ten chiral centers and two sugar substituents (L-cladinose and D-desosamine), is a good starting point for numerous medicinal chemistry efforts for improvement of its biological profile (better activity, higher stability, and improved bioavailability) since the first generation of macrolides, which had low toxicity and good tolerability, are unstable in acidic media, had low toxicity and good tolerability.

——

Davercin

GPCR/G Protein

Antibacterial

Antibacterial

Infection

——

55224-05-0

759.921

C38H65NO14

>98% (HPLC)

10 mM in DMSO

CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@H]4OC(=O)O[C@]14C

Erythromycin, cyclic 11,12-carbonate

(-20℃)

With Ice Pack

≥ 2 years